infliximab
janssen
['infliximab']
baraliakos et al. aes with sc vs iv infliximab. relatively comparable safety profiles. higher administration site reactions in sc. #acr22 abstr#1769 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC